TELMISARTAN-D3 Chemical Properties

Melting point:

262-265°C

storage temp. 

-20°C Freezer, Under Inert Atmosphere

solubility 

DMSO (Slightly), Methanol (Slightly, Heated)

form 

Solid

color 

White to Beige

TELMISARTAN-D3 Usage And Synthesis

Description

Telmisartan-d₃ is intended for use as an internal standard for the quantification of telmisartan by GC- or LC-MS. Telmisartan is a nonpeptide angiotensin (AT) II receptor antagonist which selectively and insurmountably inhibits the AT II receptor subtype AT₁ (K_i = 3.7 nM). It also acts as a partial agonist of peroxisome proliferator-activated receptor gamma (PPARγ), activating the receptor to 25-30% of that produced by the full agonist rosiglitazone (; EC₅₀ = 4.5 μM). Through these actions, telmisartan potently reduces blood pressure in various animal models of hypertension, diminishing cardiac hypertrophy, cardiovascular and renal risk, and glomerulosclerosis.

Chemical Properties

Off-White Crystalline Solid

Uses

Labelled Telmisartan, an angiotensin II receptor antagonist

Uses

TelMisartan-d3 can be intended for use as an internal standard for the quantification of Telmisartan by GC- or LC-mass spectrometry.

Uses

TelMisartan-d3 is an angiotensin II receptor antagonist.

References

[1] W. WIENEN. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277[J]. British Journal of Pharmacology, 1993, 110 1: 245-252. DOI: 10.1111/j.1476-5381.1993.tb13800.x
[2] STEPHEN C BENSON. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.[J]. Hypertension, 2004, 43 5: 993-1002. DOI: 10.1161/01.hyp.0000123072.34629.57
[3] ARONOW W S. Telmisartan[J]. Drugs, 2012, 56 1: 1045. DOI: 10.2165/00003495-199856060-00009
[4] JUGDUTT B I. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.[J]. Clinical Interventions in Aging, 2010, 5: 403-416. DOI: 10.2147/cia.s6709
[5] ROLAND E SCHMIEDER  Matthew R W  George Bakris. Telmisartan in incipient and overt diabetic renal disease.[J]. Journal of Nephrology, 2011, 24 3: 263-273. DOI: 10.5301/jn.2011.6416

TELMISARTAN-D3(1189889-44-8)Related Product Information

• tert-Butyl 4'-(bromomethyl)biphenyl-2-carboxylate
• 6-Des(1-Methyl-2-benziMidazolyl)-6-carboxy TelMisartan
• 2-n-Propyl-4-methyl-6-(1-methylbenzimidazole-2-yl)benzimidazole
• Telmisartan Related Compound B (15 mg) (4'-[(1,7'-dimethyl-2'-propyl-1H,1'H-2,5'-bibenzo[d]imidazol-1'-yl)methyl]biphenyl-2-carboxylic acid)
• propyl[2,6'-bi-1H-benzimidazol]-1'-yl]methyl]-
• TelMisartan AMide
• Telmisartan tert-Butyl Ester
• TelMisartan-13CD3
• Telmisartan